The effect of bradykinin 1 receptor antagonist BI 1026706 on pulmonary inflammation after segmental lipopolysaccharide challenge in healthy smokers.
暂无分享,去创建一个
K. Hohl | Abhya Gupta | W. Seibold | T. Litzenburger | P. Badorrek | M. Müller | J. Vogel-Claussen | Christina Gress | Marilisa Konietzke | J. Hohlfeld
[1] Xiaoyu Liu,et al. Bradykinin/bradykinin 1 receptor promotes brain microvascular endothelial cell permeability and proinflammatory cytokine release by downregulating Wnt3a , 2022, Journal of biochemical and molecular toxicology.
[2] D. Rex,et al. A comprehensive review on current understanding of bradykinin in COVID-19 and inflammatory diseases , 2022, Molecular Biology Reports.
[3] D. Proud,et al. Respiratory Viral and Bacterial Exacerbations of COPD—The Role of the Airway Epithelium , 2022, Cells.
[4] G. Donaldson,et al. Update in Chronic Obstructive Pulmonary Disease in 2020. , 2021, American Journal of Respiratory and Critical Care Medicine.
[5] J. Hohlfeld,et al. Investigating the effect of TRPV4 inhibition on pulmonary-vascular barrier permeability following segmental endotoxin challenge. , 2020, Pulmonary pharmacology & therapeutics.
[6] B. Balbi,et al. Bacterial and viral infections and related inflammatory responses in chronic obstructive pulmonary disease , 2020, Annals of medicine.
[7] D. McAuley,et al. Human lipopolysaccharide models provide mechanistic and therapeutic insights into systemic and pulmonary inflammation , 2020, European Respiratory Journal.
[8] Wenbo Tang,et al. Bradykinin 1 Receptor Antagonist BI1026706 Does Not Reduce Central Retinal Thickness in Center-Involved Diabetic Macular Edema , 2020, Translational vision science & technology.
[9] F. Wacker,et al. Noninvasive Monitoring of the Response of Human Lungs to Low‐Dose Lipopolysaccharide Inhalation Challenge Using MRI: A Feasibility Study , 2019, Journal of magnetic resonance imaging : JMRI.
[10] A. Kirsten,et al. Safety and Tolerability of Four Weeks' Treatment with a Bradykinin 1 Receptor Antagonist (BI 1026706) in Patients with COPD (GOLD I-III) , 2019, Therapy.
[11] Steven,et al. The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial , 2018, International journal of chronic obstructive pulmonary disease.
[12] M. Bader,et al. Kinin B1 receptors as a therapeutic target for inflammation , 2018, Expert opinion on therapeutic targets.
[13] M. Boskabady,et al. Experimental animal models for COPD: a methodological review , 2017, Tobacco induced diseases.
[14] Dongwon Lee,et al. Kinin B 1 Receptor Inhibition with BI 113823 Reduces Inflammatory Response , Mitigates Organ Injury , and Improves Survival in Severe Sepsis , 2015 .
[15] Malarvizhi Gurusamy,et al. Kinin B1 receptor antagonist BI113823 reduces allergen-induced airway inflammation and mucus secretion in mice. , 2016, Pharmacological research.
[16] Malarvizhi Gurusamy,et al. Kinin B1 Receptor Antagonist BI113823 Reduces Acute Lung Injury* , 2015, Critical care medicine.
[17] Dave Singh,et al. Oral and inhaled p38 MAPK inhibitors: effects on inhaled LPS challenge in healthy subjects , 2015, European Journal of Clinical Pharmacology.
[18] Dave Singh,et al. Characterization of the inflammatory response to inhaled lipopolysaccharide in mild to moderate chronic obstructive pulmonary disease. , 2015, British journal of clinical pharmacology.
[19] M. Hernandez,et al. IL-1 receptor antagonist reduces endotoxin-induced airway inflammation in healthy volunteers. , 2015, The Journal of allergy and clinical immunology.
[20] N. Alexis,et al. Effect of inhaled endotoxin on mucociliary clearance and airway inflammation in mild smokers and nonsmokers. , 2014, Journal of aerosol medicine and pulmonary drug delivery.
[21] O. Michel,et al. Anti-TNF inhibits the Airways neutrophilic inflammation induced by inhaled endotoxin in human , 2014, BMC Pharmacology and Toxicology.
[22] Yi Wu,et al. A role for bradykinin in the development of anti-collagen antibody-induced arthritis. , 2014, Rheumatology.
[23] Frank K Wacker,et al. Quantification of pulmonary inflammation after segmental allergen challenge using turbo-inversion recovery-magnitude magnetic resonance imaging. , 2014, American journal of respiratory and critical care medicine.
[24] P. Barnes,et al. Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist , 2013, Respiratory Research.
[25] D. Postma,et al. Expression of vascular remodelling markers in relation to bradykinin receptors in asthma and COPD , 2013, Thorax.
[26] N. Krug,et al. Low-dose endotoxin inhalation in healthy volunteers - a challenge model for early clinical drug development , 2013, BMC Pulmonary Medicine.
[27] Dave Singh,et al. Inhaled LPS challenges in smokers: a study of pulmonary and systemic effects. , 2012, British journal of clinical pharmacology.
[28] M. Elmlinger,et al. Repeatability of and Relationship between Potential COPD Biomarkers in Bronchoalveolar Lavage, Bronchial Biopsies, Serum, and Induced Sputum , 2012, PloS one.
[29] M. Hernandez,et al. Atopic asthmatic patients have reduced airway inflammatory cell recruitment after inhaled endotoxin challenge compared with healthy volunteers. , 2012, The Journal of allergy and clinical immunology.
[30] L. Larsson,et al. Microbiological components in mainstream and sidestream cigarette smoke , 2012, Tobacco induced diseases.
[31] E. Vaucher,et al. Ocular Application of the Kinin B1 Receptor Antagonist LF22-0542 Inhibits Retinal Inflammation and Oxidative Stress in Streptozotocin-Diabetic Rats , 2012, PloS one.
[32] I. Du Rand,et al. Summary of the British Thoracic Society Guidelines for advanced diagnostic and therapeutic flexible bronchoscopy in adults , 2011, Thorax.
[33] A. Morin,et al. Cigarette smoke-induced kinin B1 receptor promotes NADPH oxidase activity in cultured human alveolar epithelial cells , 2011, Peptides.
[34] F. Marceau,et al. Effect of interferon-γ on inflammatory cytokine-induced bradykinin B1 receptor expression in human vascular cells. , 2010, European journal of pharmacology.
[35] A. Morin,et al. Mechanism of cigarette smoke-induced kinin B1 receptor expression in rat airways , 2010, Peptides.
[36] D. Rand,et al. Dual positive and negative regulation of GPCR signaling by GTP hydrolysis. , 2009, Cellular signalling.
[37] N. Krug,et al. Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: a randomized placebo-controlled trial. , 2008, Pulmonary pharmacology & therapeutics.
[38] N. Krug,et al. Endotoxin augments myeloid dendritic cell influx into the airways in patients with allergic asthma. , 2008, American journal of respiratory and critical care medicine.
[39] R. Kitz,et al. Systemic and bronchial inflammation following LPS inhalation in asthmatic and healthy subjects , 2006, Journal of endotoxin research.
[40] K. Bhoola,et al. Activation of kinin B1 receptors induces chemotaxis of human neutrophils , 2006, Journal of leukocyte biology.
[41] W. Abraham,et al. Peptide and non-peptide bradykinin receptor antagonists: role in allergic airway disease. , 2006, European journal of pharmacology.
[42] D. Patel,et al. Acute LPS inhalation in healthy volunteers induces dendritic cell maturation in vivo. , 2005, The Journal of allergy and clinical immunology.
[43] Joachim Heinrich,et al. Metal-rich ambient particles (particulate matter 2.5) cause airway inflammation in healthy subjects. , 2004, American journal of respiratory and critical care medicine.
[44] N. Krug,et al. Natural porcine surfactant augments airway inflammation after allergen challenge in patients with asthma. , 2004, American journal of respiratory and critical care medicine.
[45] R. Chang,et al. Molecular and pharmacological diversity of the kinin B1 receptor. , 2002, International immunopharmacology.
[46] S. Banks,et al. Local inflammatory responses following bronchial endotoxin instillation in humans. , 2001, American journal of respiratory and critical care medicine.
[47] L. M. Leeb-Lundberg,et al. The Human B1 Bradykinin Receptor Exhibits High Ligand-independent, Constitutive Activity , 2001, The Journal of Biological Chemistry.
[48] J. Hasday,et al. Bacterial endotoxin is an active component of cigarette smoke. , 1999, Chest.
[49] R. Sergysels,et al. Dose-response relationship to inhaled endotoxin in normal subjects. , 1997, American journal of respiratory and critical care medicine.
[50] R. Sergysels,et al. Inflammatory response to acute inhalation of endotoxin in asthmatic patients. , 1992, The American review of respiratory disease.
[51] J. Hohlfeld,et al. The inhibition of α1-adrenoceptor-mediated contractions of rabbit pulmonary artery by Ca2+-withdrawal, pertussis toxin and N-ethylmaleimide is dependent on agonist intrinsic efficacy , 1989, Naunyn-Schmiedeberg's Archives of Pharmacology.
[52] P. Barnes,et al. Bradykinin-induced bronchoconstriction in humans. Mode of action. , 1987, The American review of respiratory disease.